<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910245</url>
  </required_header>
  <id_info>
    <org_study_id>SA652012</org_study_id>
    <nct_id>NCT02910245</nct_id>
  </id_info>
  <brief_title>Mercaptopurine Therapy in Ulcerative Colitis</brief_title>
  <acronym>OPTIC</acronym>
  <official_title>Efficacy of Optimized Thiopurine Therapy in Ulcerative Colitis (OPTIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a double-blind, randomized, placebo-controlled, multicenter trial in the
      Netherlands. The aim of this study is to investigate the therapeutic efficacy of optimized
      6-mercaptopurine (6-MP) in ulcerative colitis patients. Therapeutic drug monitoring (TDM)
      will be performed in order to optimize treatment outcomes and objective endoscopic endpoints
      will be used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive treatment with oral prednisone 40 mg/day for 2 weeks, followed by fixed
      tapering over 6 weeks. Half of the subjects will be randomized to concomitant 6-MP 1-1.5
      mg/kg/day and half will receive concomitant placebo treatment. During the entire course of
      the trial all subjects will receive maintenance treatment with 5-ASA in an oral dose of at
      least 2 gram per day. Subjects will be subjected to one colonoscopy at baseline and one
      sigmoidoscopy in week 52 in order to assess endoscopic disease activity.

      Data will be collected using electronic case report forms (eCRF) with Castor EDC. Quality and
      data validation procedures will be applied to ensure the validity and accuracy of the
      clinical database. Monitoring of the study will be done according to the GCP guidelines and
      following a monitoring plan. The financier of the study, ZonMw Goed Gebruik Geneesmiddelen,
      has the right to perform an audit if seen necessary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and endoscopic remission</measure>
    <time_frame>After 52 weeks of treatment</time_frame>
    <description>Defined as a SCCAI-score ≤ 4, a UCEIS-score ≤ 3 and a total Mayo score ≤ 2, with no individual subscore &gt;1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Serious) Adverse Events</measure>
    <time_frame>Continue during 52 weeks of treatment</time_frame>
    <description>Occurrence of (serious) adverse events ((S)AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte counts</measure>
    <time_frame>Every 6 weeks during 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>Every 6-12 weeks during 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of subjective thiopurine intolerance</measure>
    <time_frame>Every 6-12 weeks during 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-TGN levels</measure>
    <time_frame>Every 6-12 weeks during 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-MMP levels</measure>
    <time_frame>Every 6-12 weeks during 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment failure</measure>
    <time_frame>Continue during 52 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of upscaling treatment</measure>
    <time_frame>Continue during 52 weeks of treatment</time_frame>
    <description>Occurrence of upscaling treatment to biologicals (anti-TNF agents or vedolizumab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment costs</measure>
    <time_frame>Every 3 months during 52 weeks of treatment</time_frame>
    <description>Budget-impact analysis and cost-utility analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Every 3 months during 52 weeks of treatment</time_frame>
    <description>IBDQ-score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Mercaptopurine (Purinethol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks &amp; Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks &amp; Mesalamine, 2 g/day oral, 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 1-1.5 mg/kg/day, 52 weeks &amp; Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks &amp; Mesalamine, 2 g/day oral, 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine (Purinethol)</intervention_name>
    <arm_group_label>Mercaptopurine (Purinethol)</arm_group_label>
    <other_name>Purinethol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamine</intervention_name>
    <arm_group_label>Mercaptopurine (Purinethol)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Asacol</other_name>
    <other_name>Mezavant</other_name>
    <other_name>Pentasa</other_name>
    <other_name>Salofalk</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Mercaptopurine (Purinethol)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of UC by endoscopy and histopathology

          2. Patients between 18 and 80 years of age

          3. Active disease, despite oral treatment with at least 2g/day 5-ASA

          4. Treatment with oral corticosteroids is required

        Exclusion Criteria:

          1. Prior treatment with thiopurines

          2. Prior treatment with biologics (e.g. anti-TNF agents and vedolizumab)

          3. Current pregnancy (a pregnancy test will be performed if necessary according to the
             treating physician)

          4. Chronic Obstructive Pulmonary Disease (COPD)

          5. Acute coronary heart disease

          6. (Bacterial) gastroenteritis has to be treated first

          7. Coagulation disorders

          8. Active malignancy

          9. History of colonic dysplasia/cancer

         10. Extensive colonic resection, i.e. subtotal colectomy with &lt;15 cm colon in situ

         11. Concomitant therapy with drugs interfering with MP metabolism, like allopurinol,
             ribavirin or anti-epileptics.

         12. Known systemic fungal infections or parasitic infections have to be treated first

         13. Known duodenal or ventricular ulcus

         14. Substance abuse, such as alcohol (&gt; 80 gram/day - one standard glass contains 10 gram
             of alcohol), I.V. drugs and inhaled drugs. If the subject has a history of substance
             abuse, to be considered for inclusion into the protocol, the subject must have
             abstained from using the abused substance for at least 2 years. Subjects receiving
             methadone within the past 2 years are also excluded

         15. Positive tuberculosis screen (when a screening is performed at the discretion of the
             treating physician)

         16. Active hepatitis B virus or hepatitis C virus infection defined as a positive
             anti-HCV, HBsAg and/or anti-HBcore screening.

         17. Leucopenia (Neutrophil count &lt; 1,8x10^9/L)

         18. Thrombopenia (Platelets &lt; 90x10^9/L)

         19. Elevated liver enzymes (&gt;2x ULN)

         20. Abnormal renal function (eGFR&lt; 30 mL/min)

         21. Other conditions which in the opinion of the investigator may interfere with the
             subject's ability to comply with the study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Löwenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Löwenberg, MD, PhD</last_name>
    <phone>+31205667621</phone>
    <email>m.lowenberg@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara van Gennep, MD</last_name>
    <phone>+31205668708</phone>
    <email>s.vangennep@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meander MC</name>
      <address>
        <city>Amersfoort</city>
        <zip>3813 TZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bindia Jharap, MD, PhD</last_name>
      <email>b.jharap@meandermc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG West</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MC Slotervaart</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annekatrien CT Depla, MD, PhD</last_name>
      <email>actm.depla@slz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanne de Boer, MD, PhD</last_name>
      <email>khn.deboer@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sara van Gennep, MD</last_name>
      <phone>+31205667805</phone>
      <email>s.vangennep@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OLVG Oost</name>
      <address>
        <city>Amsterdam</city>
        <zip>1090 HM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JM Jansen, MD</last_name>
      <email>j.m.jansen@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Löwenberg, MD, PhD</last_name>
      <phone>+31205667621</phone>
      <email>m.lowenberg@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sara van Gennep, MD</last_name>
      <phone>+31205667805</phone>
      <email>s.vangennep@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Amstelland Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Gielen, MD</last_name>
      <email>margi@zha.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nidhi Srivastava, MD</last_name>
      <email>n.srivastava@mchaaglanden.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi Hospital</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Itta M Minderhoud</last_name>
      <email>iminderhoud@tergooi.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jan van den Brande</last_name>
      <email>jvandenbrande@tergooi.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>X.G. Vos, MD, PhD</last_name>
      <email>X.G.Vos@westfriesgasthuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Becx, MD</last_name>
      <email>m.becx@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. West</last_name>
      <email>R.West@Franciscus.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>M. Lowenberg</investigator_full_name>
    <investigator_title>Gastroenterologist</investigator_title>
  </responsible_party>
  <keyword>Therapeutic Drug Monitoring</keyword>
  <keyword>Mercaptopurine (6-MP)</keyword>
  <keyword>Thiopurine</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

